Table 1.
Patients baseline demographics and disease characteristics
| Characteristic | Selinexor 60 mg QW/BIW + carboplatin 6 AUC Q3W (N = 6) | Selinexor 60 mg QW/BIW + doxorubicin 60 mg/m2 + cyclophosphamide 600 mg/m2 Q3W (N = 4) | Selinexor 40 mg QW + FOLFIRIa (N = 3) | Selinexor 60 mg QW + irinotecan 125 mg/m2 D1 and 8 Q3W (N = 3) | Selinexor 40 mg QW + XELOXb (N = 3) | All patients (N = 19) |
|---|---|---|---|---|---|---|
| Age at consent (years) | ||||||
| Median range | 56.1 (31.2–76.1) | 61.7 (23.6–64.9) | 49.9 (38.1–70.7) | 67.8 (57.9–72.3) | 65.9 (51.8–72.8) | 60.6 (23.6–76.1) |
| Gender, N (%) | ||||||
| Male | 1 (17) | 2 (50) | 1 (33) | 1 (33) | 2 (67) | 7 (37) |
| Female | 5 (83) | 2 (50) | 2 (67) | 2 (67) | 1 (33) | 12 (63) |
| Race/ethnicity, N (%) | ||||||
| White | 4 (67) | 4 (100) | 3 (100) | 1 (33) | 3 (100) | 15 (79) |
| Hispanic | 0 | 0 | 0 | 0 | 0 | 0 |
| Black | 1 (17) | 0 | 0 | 1 (33) | 0 | 2 (11) |
| Asian | 1 (17) | 0 | 0 | 1 (33) | 0 | 2 (11) |
| ECOG performance status, N (%) | ||||||
| 0 | 1 (17) | 0 | 1 (33) | 2 (67) | 1 (33) | 5 (26) |
| 1 | 5 (83) | 4 (100) | 2 (67) | 1 (33) | 2 (67) | 14 (74) |
| Primary tumor, N (%) | ||||||
| Ovarian | 0 | 2 (50) | 0 | 0 | 0 | 2 (11) |
| Breast | 3 (50) | 0 | 0 | 0 | 0 | 3 (16) |
| Colorectal cancer | 0 | 0 | 1 (33) | 1 (33) | 1 (33) | 3 (16) |
| Endometrial/fallopian | 0 | 0 | 0 | 0 | 0 | 0 |
| Lung | 1 (17) | 0 | 0 | 0 | 0 | 1 (5) |
| Neuroendocrine | 0 | 0 | 1 (33) | 1 (33) | 0 | 2 (11) |
| Pancreas | 0 | 0 | 1 (33) | 0 | 1 (33) | 2 (11) |
| Esophageal | 0 | 0 | 0 | 0 | 0 | 0 |
| Head and neck/salivary gland | 1 (17) | 0 | 0 | 1 (33) | 0 | 2 (11) |
| Liver/cholangiocarcinoma | 0 | 0 | 0 | 0 | 1 (33) | 1 (5) |
| Sarcoma | 0 | 1 (25) | 0 | 0 | 0 | 1 (5) |
| Prostate | 0 | 1 (25) | 0 | 0 | 0 | 1 (5) |
| Others | 1 (17) | 0 | 0 | 0 | 0 | 1 (5) |
| Prior lines of systemic therapies, N (%) | ||||||
| 0–1 | 1 (17) | 0 | 0 | 0 | 0 | 1 (5) |
| 2–3 | 4 (67) | 3 (75) | 2 (67) | 2 (67) | 2 (67) | 13 (68) |
| 4–5 | 1 (17) | 1 (25) | 1 (33) | 0 | 1 (33) | 4 (21) |
| > 5 | 0 | 0 | 0 | 1 (33) | 0 | 1 (5) |
| Median range | 2.5 (1.0–4.0) | 2.0 (2.0–4.0) | 3.0 (3.0–5.0) | 3.0 (2.0–6.0) | 3.0 (2.0–4.0) | 3.0 (1.0–6.0) |
N number; ECOG Eastern Cooperative Oncology Group; QW once weekly; BIW twice weekly; AUC area under curve; mg/m2 milligrams per square meter; D1 and 8 on days 1, and 8 of each cycle; Q3W every 3 week; FOLFIRI irinotecan with fluorouracil and folinic acid; XELOX capecitabine and oxaliplatin
aFOLFIRI—irinotecan of 180 mg/m2, 5-FU continuous infusion of 2400 mg/m2, 5-FU bolus of 400 mg/m2, and leucovorin of 400 mg/m2 on days 1, and 15
bXELOX—capecitabine was dosed at 900 mg/m2 orally (PO) divided into 2 doses on days 1–14, along with oxaliplatin of 130 mg/m2 IV Q3W